Clinical Trials Logo
  1. Home
  2. Plaque-type Psoriasis
  3. NCT00763503

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Plaque-type Psoriasis Clinical Trial

Official title:
Pharmacokinetic and Pharmacodynamic Study of CD 2027 3µg/g Oily Spray Applied Twice Daily for 3 Weeks Under Conditions of Maximized Use in Adults With Plaque-type Psoriasis

Clinical Trial Summary

This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and Treatment period (Day 1/ Baseline, Day 15 and Day 22).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00763503
Study type Interventional
Source Galderma R&D
Contact
Status Completed
Phase Phase 2
Start date September 2008
Completion date February 2009
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01936688 - A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) Phase 3
Completed NCT00773734 - Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) Phase 2
Completed NCT01636687 - Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) Phase 3
Completed NCT01258088 - Safety Study of Ointment for the Treatment of Plaque-type Psoriasis Phase 1
Completed NCT01132612 - AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis Phase 2
Completed NCT00852761 - A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Phase 4
Completed NCT00625326 - Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis Phase 2
Completed NCT01412944 - Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis Phase 3
Completed NCT00521339 - Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Phase 2
Completed NCT01876875 - n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis Phase 4